首页> 外文期刊>Antiviral Research >Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays.
【24h】

Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays.

机译:乙型肝炎病毒e抗原的产生取决于HepAD38细胞培养物中的共价闭合环状(ccc)DNA,并且可以作为抗病毒筛选测定中的cccDNA替代物。

获取原文
获取原文并翻译 | 示例
           

摘要

Currently available antiviral nucleoside analogs for the treatment of chronic hepatitis B virus (HBV) infections profoundly reduce virus load, but rarely cure the virus infection. This is due, at least in part, to their failure to eliminate viral covalently closed circular (ccc) DNA from the nuclei of infected hepatocytes. To screen compound libraries for antiviral drugs targeting cccDNA, we set out to develop a cell-based assay suitable for high throughput screening. Since cccDNA is time-consuming to assay, it was desirable to use a viral gene product that could serve as a reporter for intracellular cccDNA level. We predicted that the secretion of HBV e antigen (HBeAg) by HepAD38 cells, a tetracycline inducible HBV expression cell line, would be cccDNA-dependent. This is because a large portion of pre-core mRNA leader sequence in the 5' terminus of integrated viral genome was deleted, preventing HBeAg expression from transgene, but could be restored from the 3' terminal redundancy of pre-genomic RNA during viral DNA replication and subsequent cccDNA formation. Our experimental results showed that following induction, HepAD38 produced and accumulated cccDNA, which became detectable between 7 and 8 days. HBeAg synthesis and secretion into culture fluid were dependent upon and proportional to the level of cccDNA detected. Therefore, the secretion of HBeAg by HepAD38 cells could potentially serve as a convenient reporter for the high throughput screening of novel antiviral drugs targeting HBV cccDNA.
机译:当前可用于治疗慢性乙型肝炎病毒(HBV)感染的抗病毒核苷类似物可大大降低病毒载量,但很少能治愈该病毒感染。这至少部分是由于它们未能从被感染的肝细胞核中消除病毒共价闭合的环状(ccc)DNA。为了筛选针对cccDNA的抗病毒药物的化合物文库,我们着手开发一种适用于高通量筛选的基于细胞的检测方法。由于cccDNA的测定很耗时,因此希望使用可以作为细胞内cccDNA水平报告基因的病毒基因产物。我们预测,由四环素诱导的HBV表达细胞系HepAD38细胞分泌的HBV e抗原(HBeAg)将依赖cccDNA。这是因为整合病毒基因组5'末端的大部分前核心mRNA前导序列被删除,阻止了转基因的HBeAg表达,但是可以在病毒DNA复制过程中从前基因组RNA的3'末端冗余中恢复。并随后形成cccDNA。我们的实验结果表明,诱导后,HepAD38产生并积累了cccDNA,在7至8天之间可检测到。 HBeAg的合成和分泌到培养液中取决于并与检测到的cccDNA水平成正比。因此,HepAD38细胞分泌的HBeAg可能可以作为方便的报告基因,用于高通量筛选靶向HBV cccDNA的新型抗病毒药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号